Alpha globin gene copy number and incident ischemic stroke risk among Black Americans - Ruhl, A. Parker; Jeffries, Neal; Yang, Yu; Brooks, Steven; Naik, Rakhi P.; Pecker, Lydia H.; Mott, Bryan T.; Winkler, Cheryl A.; Armstrong, Nicole D.; Zakai, Neil A.; Gutierrez, Orlando M.; Judd, Suzanne; et al. (medRxiv, 2023)
Introduction People with African ancestry have greater stroke risk and greater heritability of stroke risk than people of other ancestries. Given the importance of NO in stroke, we examined the association between alpha globin gene (HBA) copy number and incident ischemic stroke in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.Methods Among 9,999 Black REGARDS participants9 with HBA and HBB genotyping available, 8,947 participants had no self-reported history of stroke at baseline and complete follow-up data. Incident ischemic stroke was defined as non-hemorrhagic stroke with a focal neurological deficit lasting ≥ 24 hours confirmed by the medical record or a focal or non-focal neurological deficit with positive imaging confirmed with medical records. Genomic DNA was analyzed using droplet digital PCR to determine HBA copy number. Multivariable Cox proportional hazards regression was used to estimate the hazard ratio (HR) of HBA copy number on time to first ischemic stroke.Results Four-hundred seventy-nine (5.3%) participants had an ischemic stroke over a median (IQR) of 11.0 (5.7, 14.0) years’ follow-up. HBA gene copy number ranged from 2 to 6: 368 (4%) -α/-α, 2,480 (28%) -α/αα, 6,014 (67%) αα/αα, 83 (1%) ααα/αα and 2 (<1%) ααα/ααα. The HR of ischemic stroke with HBA copy number, adjusted for age, sex, hypertension, atrial fibrillation, LVH, diabetes, and smoking, was 1.04; 95%CI 0.89, 1.21; p = 0.66.Conclusions Although a reduction in HBA copy number is expected to increase endothelial nitric oxide signaling in the human vascular endothelium, HBA copy number was not associated with incident ischemic stroke in this large longitudinal cohort of Black Americans. This finding is consistent with a prior study demonstrating no association between HBA copy number and hypertension but differs from a study demonstrating an association with chronic and end-stage kidney disease in which HBA gene deletions are protective. Together, these population studies suggest that the physiological roles of alpha globin may differ between the renal and cerebral vascular beds.Competing Interest StatementDr. Gutierrez receives funding from GlaxoSmithKline; consulting fees from Reata, AstraZeneca, and Ardelyx; funding and consulting fees from Akebia Therapeutics, Amgen. He serves on a data monitoring committee for QED Therapeutics.Funding StatementNIH U01 NS041588 (M.C.); AI001150 (H.C.A), HL006196 (H.C.A.); HHSN26120080001E (C.A.W); K08HL12510 (R.P.N.) and K08HL096841 (N.A.Z.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided oral and written informed consent. The Institutional Review Board of the University of Alabama at Birmingham, the lead study center, approved this study. In addition, the REGARDS study was approved by participating center Institutional Review Boards.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available from the University of Alabama (regardsadminatuab.edu).